Dr Chiara Mercinelli speaks to ecancer about the first results of NURE-Combo, a phase 2 study of neoadjuvant nivolumab and nab-paclitaxel followed by postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer.

The initial findings from the Nure-Combo trial indicate that nivolumab and nab-paclitaxel, a new chemo-immunotherapy combination, could be a safe and effective perioperative strategy for patients with MIBC.

This treatment approach has sustained efficacy post-radical cystectomy, and it may expand the options for chemotherapy combinations in patients who are ineligible for cisplatin.

Additionally, these results support the use of clinical complete response to consider organ-sparing approaches.